Edgewise Therapeutics (EWTX) Gains from Sales and Divestitures (2023 - 2025)

Edgewise Therapeutics has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $213411.0 for Q4 2025.

• Gains from Sales and Divestitures for Q4 2025 came in at $213411.0, up 151.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $213411.0 (up 151.5% YoY), and the FY2025 annual result was $213411.0, up 151.5% from the prior year.
• Gains from Sales and Divestitures came in at $213411.0 for Q4 2025 at Edgewise Therapeutics, up from $84855.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $213411.0 in Q4 2025 to a low of $84855.0 in Q4 2024.
• The 3-year median for Gains from Sales and Divestitures is $89183.0 (2023), against an average of $129149.7.
• Across the five-year window, Gains from Sales and Divestitures retreated 4.85% in 2024 and surged 151.5% in 2025, its largest moves.
• Edgewise Therapeutics' Gains from Sales and Divestitures stood at $89183.0 in 2023, then declined by 4.85% to $84855.0 in 2024, then soared by 151.5% to $213411.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $213411.0 (Q4 2025), $84855.0 (Q4 2024), and $89183.0 (Q4 2023), per Business Quant data.